Citation
Bunin, Deborah I., Kyuri Kim, Toufan Parman, Janet Gahagen, Mary B. Zelinski, Tiffany Adevai, Christina Wang et al. “Evaluation of dimethandrolone undecanoate in non‐human primates as a candidate for long‐acting injectable male contraceptive.” Andrology (2024).
Abstract
Dimethandrolone undecanoate (DMAU) is under development as a single agent hormonal male contraceptive. DMAU is a prodrug hydrolyzed by esterase(s) to the active metabolite dimethandrolone (DMA) which has dual androgenic and progestogenic actions. Phase 1 clinical trial results show DMAU to be well-tolerated as an oral contraceptive in healthy men; however, delivery of DMAU as a long-acting injectable rather than a daily oral formulation would provide user compliance benefits and address oral bioavailability concerns.
